Exosomes From M2 Macrophage Promote Peritendinous Fibrosis Posterior Tendon Injury via the MiR-15b-5p/FGF-1/7/9 Pathway by Delivery of circRNA-Ep400.
FGF-1/7/9
M2 macrophage
circRNA-Ep400
exosomes
miR-15b-5p
tendon injury
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
08
2020
accepted:
24
05
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Achilles tendon rupture prognosis is usually unsatisfactory. After the tendon is injured, it may not function properly because of the fibrotic healing response, which restrains tendon motion. Inflammatory monocytes and tissue-resident macrophages are indispensable regulators in tissue repair, fibrosis, and regeneration. Exosomes from macrophages are crucial factors in tissue microenvironment regulation following tissue injury. This study therefore aimed to clarify the roles of macrophage exosomes in tendon injury (TI) repair. The results show that macrophages play a role after TI. M1 macrophages were increased relative to peritendinous fibrosis after TI. High-throughput sequencing showed abnormal expression of circular RNAs (circRNAs) between exosomes from M2 and M0 macrophages. Among the abnormal expressions of circRNA, circRNA-Ep400 was significantly increased in M2 macrophage exosomes. The results also show that M2 macrophage-derived circRNA-Ep400-containing exosomes are important for promoting peritendinous fibrosis after TI. Bioinformatics and dual-luciferase reporting experiments confirmed that miR-15b-5p and fibroblast growth factor (FGF)-1/7/9 were downstream targets of circRNA-Ep400. High circRNA-Ep400-containing exosome treatment inhibited miR-15b-5p, but promoted FGF1/7/9 expression in both fibroblasts and tenocytes. Furthermore, high circRNA-Ep400-containing exosome treatment promoted fibrosis, proliferation, and migration in both fibroblasts and tenocytes. Taken together, the results show that M2 macrophage-derived circRNA-Ep400-containing exosomes promote peritendinous fibrosis after TI via the miR-15b-5p/FGF-1/7/9 pathway, which suggests novel therapeutics for tendon injury treatment.
Identifiants
pubmed: 34513819
doi: 10.3389/fcell.2021.595911
pmc: PMC8432299
doi:
Types de publication
Journal Article
Langues
eng
Pagination
595911Informations de copyright
Copyright © 2021 Yu, Sun, Wang, Yang, Cui, Lin, Jin and Yi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Curr Opin Infect Dis. 2011 Jun;24(3):230-4
pubmed: 21311324
Drug Des Devel Ther. 2018 Mar 20;12:591-603
pubmed: 29593382
BMJ. 1995 Jun 10;310(6993):1534
pubmed: 7787617
Nat Commun. 2015 Oct 05;6:8523
pubmed: 26436920
Adv Exp Med Biol. 2018;1087:67-79
pubmed: 30259358
Clin Orthop Surg. 2014 Jun;6(2):196-202
pubmed: 24900902
Nanomedicine. 2014 Oct;10(7):1517-27
pubmed: 24685946
Nat Immunol. 2010 Oct;11(10):936-44
pubmed: 20729857
Acta Biomater. 2018 Apr 1;70:237-248
pubmed: 29425717
Nature. 2017 Feb 23;542(7642):450-455
pubmed: 28199304
Sci Rep. 2016 Apr 20;6:24838
pubmed: 27094081
Cytotechnology. 2014 Jan;66(1):27-35
pubmed: 23299298
Nature. 2015 Nov 5;527(7576):100-104
pubmed: 26479035
J Clin Invest. 2018 Feb 1;128(2):846-860
pubmed: 29355842
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Med Sci Monit Basic Res. 2018 Apr 30;24:70-78
pubmed: 29706616
J Clin Invest. 2016 Apr 1;126(4):1139-43
pubmed: 27035805
J Bone Joint Surg Am. 2008 Mar;90(3):565-79
pubmed: 18310707
Biochem Pharmacol. 2018 Aug;154:203-212
pubmed: 29753749
Int Immunopharmacol. 2019 Oct;75:105795
pubmed: 31421547
Mol Ther. 2017 Jan 4;25(1):192-204
pubmed: 28129114
J Orthop Res. 2015 Jun;33(6):832-9
pubmed: 25641114
Acupunct Med. 2015 Feb;33(1):58-64
pubmed: 25335789
Cytokine. 2018 May;105:63-72
pubmed: 29459345
Mol Ther. 2016 May;24(5):915-25
pubmed: 26883801
J Immunol. 2008 Sep 15;181(6):3733-9
pubmed: 18768823
Mol Ther Nucleic Acids. 2019 Mar 1;14:114-130
pubmed: 30594070
Biochem Biophys Res Commun. 2020 Jan 1;521(1):91-97
pubmed: 31629466
J Immunol. 2006 Aug 1;177(3):1393-9
pubmed: 16849442
Cell. 2017 Oct 5;171(2):372-384.e12
pubmed: 28942920
Curr Opin Pharmacol. 2013 Aug;13(4):555-64
pubmed: 23747023
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
J Am Coll Cardiol. 2019 Dec 24;74(25):3124-3135
pubmed: 31856969
Nat Med. 2012 Jul 06;18(7):1028-40
pubmed: 22772564
J Am Soc Nephrol. 2017 Jul;28(7):2053-2067
pubmed: 28209809